# Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma

> **NCT00865969** · PHASE2 · COMPLETED · sponsor: **Spectrum Pharmaceuticals, Inc** · enrollment: 129 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT00865969
- **Lead sponsor:** Spectrum Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12-15
- **Primary completion:** 2013-11-05
- **Final completion:** 2014-10-27
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2021-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00865969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00865969, "Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00865969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*